Home > Healthcare > Medical Devices > Diagnostic Devices > Respiratory Disease Testing Market

Respiratory Disease Testing Market Size

Report ID: GMI1871
Published Date: Apr 2023
Report Format: PDF

Download Free Sample

Respiratory Disease Testing Market Size

Respiratory Disease Testing Market size was worth USD 14 billion in 2022 and is anticipated to exhibit 6.5% CAGR from 2023-2032. Rising burden of pulmonary and hospital-acquired infections is likely to favor market dynamics.

Respiratory Disease Testing Market

To get key market trends

Download Free Sample

The growing number of government-led initiatives, specifically in the developed and developing regions will complement the market expansion. Several government bodies are coming up with awareness programs for educating the mass population about various respiratory disorders and their prevention. To illustrate, the National Heart, Lung, and Blood Institute introduced the COPD Learn More Breathe Better (LMBB) campaign for instigating higher awareness along with educating the public regarding COPD (chronic obstructive pulmonary diseases). The campaign is also directed at offering early detection and treatment to individuals affected by various lung diseases.

Respiratory Disease Testing Market Report Attributes
Report Attribute	Details
Base Year:	2022
Respiratory Disease Testing Market Size in 2022:	USD 14 Billion
Forecast Period:	2023 to 2032
Forecast Period 2023 to 2032 CAGR:	6.5%
2032 Value Projection:	USD 26 Billion
Historical Data for:	2018 to 2022
No. of Pages:	446
Tables, Charts & Figures:	202
Segments covered:	Test Type, Application, End use, and Region
Growth Drivers:	Increasing government initiatives in developed and developing countries Rising prevalence of chronic obstructive pulmonary disease (COPD) Increasing healthcare spending by public and private organizations Exposure to dust particles and increasing number of cigarette smokers in developing as well as underdeveloped regions
Pitfalls & Challenges:	High cost of respiratory disease testing devices Unfavorable reimbursement scenario

Learn more about the key segments shaping this market

Download Free Sample

Authors: Mariam Faizullabhoy

Frequently Asked Questions (FAQ) :

Global market for respiratory disease testing reached USD 14 billion in 2022 and will exhibit 6.5% CAGR from 2023-2032 due to the growing number of government-led initiatives.

In vitro diagnostics tests will showcase more than 6% CAGR from 2023-2032 owing to their multiple advantages in the diagnosis and treatment of respiratory conditions.

The respiratory disease testing market in North America will record 6.4% CAGR from 2023-2032 on account of the strong presence of well-developed healthcare infrastructure in the region.

Abbott, Becton, Dickinson, and Company, Koninklijke Philips N.V., ResMed, VYAIRE MEDICAL, INC., Fischer & Paykel, Medtronic, BioMerieux SA, Cosmed, Seegene Inc., SDI Diagnostics, and Siemens Healthineers are the major market participants.